Myriad Genetics, Inc. (MYGN)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Myriad Genetics, Inc. (MYGN)
Go deeper and ask any question about MYGN
Company Performance
Current Price
as of Sep 13, 2024$27.59
P/E Ratio
N/A
Market Cap
$2.51B
Description
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.
Metrics
Overview
- HQSalt Lake City, UT
- SectorHealth Technology
- IndustryMedical Specialties
- TickerMYGN
- Price$27.59+4.55%
Trading Information
- Market Cap$2.51B
- Float96.00%
- Average Daily Volume (1m)627,951
- Average Daily Volume (3m)781,194
- EPS-$1.81
Company
- Revenue$802.20M
- Rev Growth (1yr)15.26%
- Net Income-$36.70M
- Gross Margin64.54%
- EBITDA Margin-4.59%
- EBITDA-$9.70M
- EV$2.26B
- EV/Revenue2.82
- P/EN/A
- P/S3.12